Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: A randomized clinical trial
Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: A randomized clinical trial
复制标题
DOI：
10.1200/jco.2002.20.2.371
复制
发表时间：
2002-01-15
影响因子：
45.3
通讯作者：
Dagnelie, PC
中科院分区：
文献类型：
--
作者：
Agteresch, HJ;Rietveld, T;Dagnelie, PC
目的：在一项针对晚期非小细胞肺癌（NSCLC）患者的随机临床试验中，输注5 '-三磷酸腺苷（ATP）可抑制体重减轻和生活质量下降。在本文中，ATP对身体组成，能量摄入和能量消耗的影响！患者和方法：IIIB或IV期NSCLC患者随机接受10次静脉内30小时ATP输注，每2至4周一次或不接受ATP。每隔4周评估一次脂肪质量（M）、去脂肪质量（FFM）和手臂肌肉面积，持续28周。每隔8周评估一次食物摄入量、体细胞质量（BMD）和静息能量消耗（REE），持续16周。组间差异进行了测试，通过重复测量的协方差analysis of covariance.Results的统计学意义：58例患者被随机分组（28 ATP，30对照）。在28周的随访期内，ATP组的身体成分没有变化，而对照组每4周减少0.6 kg FM（P = 0.004），0.5公斤FFM（P = 0.02），1.8%的手臂肌肉面积（P = 0.02）和0.6%的体重/kg体重（P = 0.054），并减少568 KJ/d的能量摄入（P = 0.0001）。ATP组的食欲也保持稳定，但对照组显著下降（P = .0004）。ATP和对照组之间的REE无显着差异observed.Conclusion：ATP输注抑制晚期NSCLC患者的体重减轻是由于抵消代谢活性和非活性组织的损失。这些影响部分归因于维持能量摄入。(C)2002年，美国临床肿瘤学会。
Purpose: In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life. In the present article, the effects of ATP on body composition, energy intake, and energy expenditure! as secondary outcome measures in the same patients are reported.Patients and Methods: Patients with NSCLC, stage IIIB or IV, were randomized to receive either 10 intravenous, 30-hour ATP infusions every 2 to 4 weeks or no ATP. Fat mass (M), fat-free mass (FFM), and arm muscle area were assessed at 4-week intervals for 28 weeks. Food intake, body cell mass (BCM), and resting energy expenditure (REE) were assessed at 8-week intervals for 16 weeks. Between-group differences were tested for statistical significance by repeated-measures analysis of covariance.Results: Fifty-eight patients were randomized (28 ATP, 30 control). No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P = .004), 0.5 kg of FFM(P = .02), 1.8% of arm muscle area (P = .02), and 0.6% of BCM/kg body weight (P = .054) and decreased 568 KJ/d in energy intake (P = .0001). Appetite also remained stable in the ATP group but decreased significantly in the control group (P = .0004). No significant differences in REE between the ATP and control groups were observed.Conclusion: The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues. These effects are partly ascribed to maintenance of energy intake. (C) 2002 by American Society of Clinical Oncology.